192 related articles for article (PubMed ID: 35512065)
1. Design, synthesis, and biological evaluation of histone deacetylase inhibitor with novel salicylamide zinc binding group.
Kim JH; Ali KH; Oh YJ; Seo YH
Medicine (Baltimore); 2022 Apr; 101(17):e29049. PubMed ID: 35512065
[TBL] [Abstract][Full Text] [Related]
2. Investigation of the effect of different linker chemotypes on the inhibition of histone deacetylases (HDACs).
Linciano P; Benedetti R; Pinzi L; Russo F; Chianese U; Sorbi C; Altucci L; Rastelli G; Brasili L; Franchini S
Bioorg Chem; 2021 Jan; 106():104462. PubMed ID: 33213894
[TBL] [Abstract][Full Text] [Related]
3. Isoform-selective HDAC1/6/8 inhibitors with an imidazo-ketopiperazine cap containing stereochemical diversity.
Lecointre B; Narozny R; Borrello MT; Senger J; Chakrabarti A; Jung M; Marek M; Romier C; Melesina J; Sippl W; Bischoff L; Ganesan A
Philos Trans R Soc Lond B Biol Sci; 2018 Jun; 373(1748):. PubMed ID: 29685969
[TBL] [Abstract][Full Text] [Related]
4. Syntheses and Biological Evaluation of Novel Hydroxamic Acid Derivatives Containing Purine Moiety as Histone Deacetylase Inhibitors.
Xu Z; Yang Y; Mai X; Liu B; Xiong Y; Feng L; Liao Y; Zhang Y; Wang H; Ouyang L; Liu S
Chem Pharm Bull (Tokyo); 2018; 66(4):439-451. PubMed ID: 29607910
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
Tashima T; Murata H; Kodama H
Bioorg Med Chem; 2014 Jul; 22(14):3720-31. PubMed ID: 24864038
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of phenothiazine derivative-containing hydroxamic acids as potent class II histone deacetylase inhibitors.
Hsu KC; Chu JC; Tseng HJ; Liu CI; Wang HC; Lin TE; Lee HS; Hsin LW; Wang AH; Lin CH; Huang WJ
Eur J Med Chem; 2021 Jul; 219():113419. PubMed ID: 33845233
[TBL] [Abstract][Full Text] [Related]
7. Carbamates as Potential Prodrugs and a New Warhead for HDAC Inhibition.
King K; Hauser AT; Melesina J; Sippl W; Jung M
Molecules; 2018 Feb; 23(2):. PubMed ID: 29393896
[TBL] [Abstract][Full Text] [Related]
8. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
Senger J; Melesina J; Marek M; Romier C; Oehme I; Witt O; Sippl W; Jung M
J Med Chem; 2016 Feb; 59(4):1545-55. PubMed ID: 26653328
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
[TBL] [Abstract][Full Text] [Related]
11. Diarylcyclopropane hydroxamic acid inhibitors of histone deacetylase 4 designed by combinatorial approach and QM/MM calculations.
Kollar J; Frecer V
J Mol Graph Model; 2018 Oct; 85():97-110. PubMed ID: 30145395
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
Yang Z; Shen M; Tang M; Zhang W; Cui X; Zhang Z; Pei H; Li Y; Hu M; Bai P; Chen L
Eur J Med Chem; 2019 Sep; 178():116-130. PubMed ID: 31177073
[TBL] [Abstract][Full Text] [Related]
13. Zinc-dependent histone deacetylases: Potential therapeutic targets for arterial hypertension.
Kee HJ; Kim I; Jeong MH
Biochem Pharmacol; 2022 Aug; 202():115111. PubMed ID: 35640713
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of N-hydroxycinnamides capped with a naturally occurring moiety as inhibitors of histone deacetylase.
Huang WJ; Chen CC; Chao SW; Lee SS; Hsu FL; Lu YL; Hung MF; Chang CI
ChemMedChem; 2010 Apr; 5(4):598-607. PubMed ID: 20209563
[TBL] [Abstract][Full Text] [Related]
15. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of HDAC6 inhibitors targeting L1 loop and serine 531 residue.
Jha S; Kim JH; Kim M; Nguyen AH; Ali KH; Gupta SK; Park SY; Ha E; Seo YH
Eur J Med Chem; 2024 Feb; 265():116057. PubMed ID: 38142511
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase 1/mSin3A disrupts gamma interferon-induced CIITA function and major histocompatibility complex class II enhanceosome formation.
Zika E; Greer SF; Zhu XS; Ting JP
Mol Cell Biol; 2003 May; 23(9):3091-102. PubMed ID: 12697811
[TBL] [Abstract][Full Text] [Related]
18. Trichostatin A induces 5-lipoxygenase promoter activity and mRNA expression via inhibition of histone deacetylase 2 and 3.
Pufahl L; Katryniok C; Schnur N; Sorg BL; Metzner J; Grez M; Steinhilber D
J Cell Mol Med; 2012 Jul; 16(7):1461-73. PubMed ID: 21883892
[TBL] [Abstract][Full Text] [Related]
19. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
Beyer M; Kiweler N; Mahboobi S; Krämer OH
Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
[TBL] [Abstract][Full Text] [Related]
20. Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines.
Sixto-López Y; Gómez-Vidal JA; de Pedro N; Bello M; Rosales-Hernández MC; Correa-Basurto J
Sci Rep; 2020 Jun; 10(1):10462. PubMed ID: 32591593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
